Expression, purification and characterization of secreted recombinant human insulin-like growth factor-I (IGF-I) and the potent variant des(1-3) IGF-I in Chinese hamster ovary cells.

McKinnon P, Ross M, Wells JR, Ballard FJ, Francis GL

Journal of molecular endocrinology1 Jun 1991Cited by 7 (Europe PMC)

PMID1883485DOI10.1677/jme.0.0060231PepBankPUB-01883485

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of IGF-1 (mecasermin) aloneIn vitro (cells)Other
Transfected Chinese hamster ovary clones secreted correctly processed recombinant human IGF-I with IGF-I-like activity in culture medium.
In plain wordsIn cells, transfected Chinese hamster ovary clones secreted correctly processed human IGF-I with biological activity.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableSecretion of correctly processed recombinant IGF-I
Study
n: not reported in source
Transfected Chinese hamster ovary cells
Outcome group
Synthesis and manufacturing · Pharmacology
Source sentences
Summary
Successfully transfected clones secreting correctly processed recombinant hIGF-I or des(1-3)IGF-I were selected by their secretion of IGF-I-like activity into the culture medium.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0188348505
02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Other
Transfected Chinese hamster ovary clones secreted correctly processed recombinant des(1‑3)IGF-I with IGF-I-like activity in culture medium.
In plain wordsIn cells, transfected Chinese hamster ovary clones secreted correctly processed des(1‑3)IGF-I with biological activity.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Not applicableSecretion of correctly processed recombinant des(1-3)IGF-I
Study
n: not reported in source
Transfected Chinese hamster ovary cells
Outcome group
Synthesis and manufacturing · Pharmacology
Source sentences
Summary
Successfully transfected clones secreting correctly processed recombinant hIGF-I or des(1-3)IGF-I were selected by their secretion of IGF-I-like activity into the culture medium.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0188348506
03LabNot a test of IGF-1 (mecasermin) aloneIn vitro (cell-free)Other
In laboratory characterization, recombinant human IGF-I was purified to homogeneity.
In plain wordsIn lab tests, recombinant human IGF-I was purified to homogeneity.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicablePurification homogeneity
Study
n: not reported in source
Purified recombinant peptides
Outcome group
Synthesis and manufacturing · Pharmacology
Source sentences
Summary
The recombinant peptides were purified to homogeneity as assessed by high-performance liquid chromatography and N-terminal sequence analysis.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0188348501
04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Other
In laboratory characterization, recombinant des(1‑3)IGF-I was purified to homogeneity.
In plain wordsIn lab tests, recombinant des(1‑3)IGF-I was purified to homogeneity.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Not applicablePurification homogeneity
Study
n: not reported in source
Purified recombinant peptides
Outcome group
Synthesis and manufacturing · Pharmacology
Source sentences
Summary
The recombinant peptides were purified to homogeneity as assessed by high-performance liquid chromatography and N-terminal sequence analysis.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0188348502
05LabNot a test of IGF-1 (mecasermin) aloneOther designActivity measurement
In laboratory tests, purified recombinant human IGF-I had biological potency equivalent to authentic IGF-I.
In plain wordsIn lab tests, recombinant human IGF-I had the same biological potency as authentic IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBiological potency
Study
n: not reported in source
Purified recombinant peptides
Comparator
Authentic IGF-I
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The purified recombinant peptides exhibited biological potencies equivalent to authentic IGF-I and des(1-3)IGF-I respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 (mecasermin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 (mecasermin).
Report a problemFND-0188348503
06LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneOther designActivity measurement
In laboratory tests, purified recombinant des(1‑3)IGF-I had biological potency equivalent to authentic des(1‑3)IGF-I.
In plain wordsIn lab tests, recombinant des(1‑3)IGF-I had the same biological potency as authentic des(1‑3)IGF-I.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
No significant changeBiological potency
Study
n: not reported in source
Purified recombinant peptides
Comparator
Authentic des(1-3)IGF-I
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The purified recombinant peptides exhibited biological potencies equivalent to authentic IGF-I and des(1-3)IGF-I respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Recombinant human insulin-like growth factor-I (hIGF-I) and a biologically potent variant lacking the N-terminal tripeptide (des(1-3)IGF-I) were produced from transfected Chinese hamster ovary cells.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0188348504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
21 Oct 2026, 15:58 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 13:52 UTC
The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.